According to Shenlian Biotech's announcement, it achieved operating income of 112 million yuan in the first half of 2026, a year-on-year decrease of 8.05%; net loss attributable to shareholders of listed companies of 19.1464 million yuan, net loss of 12.8697 million yuan for the same period last year; and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 19.15,800 yuan. R&D investment accounted for 19.91% of revenue, a year-on-year decrease of 2.41 percentage points. The company achieved the holding of WorldSource step by step and strategically entered the field of innovative pharmaceuticals.

According to Shenlian Biotech's announcement, it achieved operating income of 112 million yuan in the first half of 2026, a year-on-year decrease of 8.05%; net loss attributable to shareholders of listed companies of 19.1464 million yuan, net loss of 12.8697 million yuan for the same period last year; and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 19.15,800 yuan. R&D investment accounted for 19.91% of revenue, a year-on-year decrease of 2.41 percentage points. The company achieved the holding of WorldSource step by step and strategically entered the field of innovative pharmaceuticals.